Previous 10 | Next 10 |
Synthetic Biologics, Inc. (SYN) Q3 2019 Earnings Conference Call November 04, 2019, 16:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communications Steven Shallcross - CEO and CFO Michael Kaleko - SVP of Research and Development Vince Wacher - Head of Prod...
Synthetic Biologics (NYSEMKT: SYN ): Q3 GAAP EPS of -$0.31. More news on: Synthetic Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
ROCKVILLE, Md. , Nov. 4, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provi...
ROCKVILLE, Md. , Oct. 28, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, annou...
In our most recent article, we focused on Iovance ( IOVA ), a cell therapy company that in our opinion has consistently generated positive data, has developed a commercializable product, and is deploying a de-risked clinical strategy for a clear unmet need. As a result, we saw nearly 100% ups...
ROCKVILLE, Md. , Sept. 26, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Offic...
Synthetic Biologics, Inc (SYN) Q2 2019 Earnings Conference Call August 08, 2019 04:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communication Steven Shallcross - Chief Executive Officer & Chief Financial Officer Vince Wacher - Head of Product & Corp...
Synthetic Biologics (NYSEMKT: SYN ): Q2 GAAP EPS of -$0.23. Cash and cash equivalents of $21.7M Shares +3% Press Release More news on: Synthetic Biologics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
ROCKVILLE, Md. , Aug. 8, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reporte...
ROCKVILLE, Md. , Aug. 1, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its op...
News, Short Squeeze, Breakout and More Instantly...
Synthetic Biologics Inc. Company Name:
SYN Stock Symbol:
NYSE Market:
Synthetic Biologics Inc. Website:
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and branding elements were introduced to better ref...
ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from collaborators at Fund...
- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical...